DK3270923T3 - Terapeutisk middel til frontallapsdysfunktion - Google Patents

Terapeutisk middel til frontallapsdysfunktion Download PDF

Info

Publication number
DK3270923T3
DK3270923T3 DK16765135.5T DK16765135T DK3270923T3 DK 3270923 T3 DK3270923 T3 DK 3270923T3 DK 16765135 T DK16765135 T DK 16765135T DK 3270923 T3 DK3270923 T3 DK 3270923T3
Authority
DK
Denmark
Prior art keywords
frontallaps
dysfunction
therapeutic medicine
therapeutic
medicine
Prior art date
Application number
DK16765135.5T
Other languages
English (en)
Inventor
Takako Horita
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Application granted granted Critical
Publication of DK3270923T3 publication Critical patent/DK3270923T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16765135.5T 2015-03-19 2016-03-18 Terapeutisk middel til frontallapsdysfunktion DK3270923T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015055532 2015-03-19
PCT/JP2016/059788 WO2016148308A1 (en) 2015-03-19 2016-03-18 Therapeutic agent for frontal lobe dysfunction

Publications (1)

Publication Number Publication Date
DK3270923T3 true DK3270923T3 (da) 2021-08-23

Family

ID=56919157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16765135.5T DK3270923T3 (da) 2015-03-19 2016-03-18 Terapeutisk middel til frontallapsdysfunktion

Country Status (39)

Country Link
US (2) US20180042910A1 (da)
EP (1) EP3270923B1 (da)
JP (1) JP6869893B2 (da)
KR (1) KR20170129764A (da)
CN (1) CN107405341A (da)
AR (1) AR103972A1 (da)
AU (1) AU2016234211B2 (da)
BR (1) BR112017018165A2 (da)
CA (1) CA2978426A1 (da)
CL (1) CL2017002351A1 (da)
CO (1) CO2017008814A2 (da)
CR (1) CR20170405A (da)
CY (1) CY1124459T1 (da)
DK (1) DK3270923T3 (da)
DO (1) DOP2017000206A (da)
EA (1) EA032511B1 (da)
EC (1) ECSP17069712A (da)
ES (1) ES2884846T3 (da)
GE (1) GEP20197007B (da)
HK (1) HK1249059A1 (da)
HR (1) HRP20211340T1 (da)
HU (1) HUE055387T2 (da)
IL (1) IL254196A0 (da)
JO (1) JO3544B1 (da)
LT (1) LT3270923T (da)
MX (1) MX2017012020A (da)
MY (1) MY196076A (da)
PE (1) PE20171621A1 (da)
PL (1) PL3270923T3 (da)
PT (1) PT3270923T (da)
RS (1) RS62311B1 (da)
SG (1) SG11201707012YA (da)
SI (1) SI3270923T1 (da)
SV (1) SV2017005527A (da)
TN (1) TN2017000369A1 (da)
TW (1) TWI723012B (da)
UA (1) UA123578C2 (da)
WO (1) WO2016148308A1 (da)
ZA (1) ZA201706136B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113016719B (zh) * 2019-12-24 2022-08-02 复旦大学附属华山医院 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727259B2 (en) 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
SI1700856T1 (sl) * 2003-12-26 2016-02-29 Kyowa Hakko Kirin Co., Ltd., Tiazolni derivat
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
WO2012060844A1 (en) 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers

Also Published As

Publication number Publication date
TN2017000369A1 (en) 2019-01-16
SG11201707012YA (en) 2017-09-28
PT3270923T (pt) 2021-08-26
US20210393606A1 (en) 2021-12-23
CR20170405A (es) 2018-01-30
ES2884846T3 (es) 2021-12-13
EA032511B1 (ru) 2019-06-28
CL2017002351A1 (es) 2018-03-16
SV2017005527A (es) 2017-10-23
ZA201706136B (en) 2019-01-30
PE20171621A1 (es) 2017-11-02
PL3270923T3 (pl) 2021-12-20
UA123578C2 (uk) 2021-04-28
JP2018508540A (ja) 2018-03-29
HRP20211340T1 (hr) 2021-11-26
HUE055387T2 (hu) 2021-11-29
MX2017012020A (es) 2018-01-30
AR103972A1 (es) 2017-06-14
KR20170129764A (ko) 2017-11-27
EP3270923A1 (en) 2018-01-24
BR112017018165A2 (pt) 2018-04-10
RS62311B1 (sr) 2021-09-30
AU2016234211B2 (en) 2020-08-27
EP3270923B1 (en) 2021-05-26
GEP20197007B (en) 2019-07-25
CN107405341A (zh) 2017-11-28
US20180042910A1 (en) 2018-02-15
JO3544B1 (ar) 2020-07-05
DOP2017000206A (es) 2017-12-31
IL254196A0 (en) 2017-10-31
WO2016148308A1 (en) 2016-09-22
AU2016234211A1 (en) 2017-10-12
SI3270923T1 (sl) 2021-10-29
ECSP17069712A (es) 2018-02-28
JP6869893B2 (ja) 2021-05-12
CY1124459T1 (el) 2022-07-22
HK1249059A1 (zh) 2018-10-26
MY196076A (en) 2023-03-13
CA2978426A1 (en) 2016-09-22
EP3270923A4 (en) 2018-11-07
TW201705957A (zh) 2017-02-16
LT3270923T (lt) 2021-09-10
TWI723012B (zh) 2021-04-01
EA201792070A1 (ru) 2018-01-31
CO2017008814A2 (es) 2018-01-16

Similar Documents

Publication Publication Date Title
DK3328880T3 (da) Terapeutiske midler
BR112018009951A2 (pt) fármaco oftálmico
DK3356313T3 (da) 2-perfluorhexyloktan til oftalmisk indgivelse
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3171929T3 (da) Dosering til nervestimulation
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3139986T3 (da) System til administration af terapeutisk gas
DK3265421T3 (da) Doseringssystem
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
BR112016026879A2 (pt) Composição farmacêutica líquida
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
MA39483A (fr) Agents thérapeutiques cibles
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3363428T3 (da) Perfusionsdoseringsform
DK3199161T3 (da) Farmaceutisk præparat
DK3393478T3 (da) Kombinationsterapi
DK3463345T3 (da) Farmaceutiske kombinationer
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK2974728T3 (da) Terapeutisk middel til meibomsk dysfunktion